Prohost BiotechResearch Platform

Home Articles Prohost LettersProhost Letter #401

Prohost Letters

Premium

Prohost Letter #401

Prohost Letter #401 SYNOPSIS PART 1 In this Letter CONTENTS Duchenne Muscular Dystrophy (DMD) FDA Compassionate Approval of Eteplirsen! PART 2 In The Letter Issue #402 CONTENTS EYE ON IONIS (IONS) Ant...

P

Prohost Biotech

November 16, 2016

1 min read

5

0

Unlock Premium Content

This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.

Unlimited articles

Expert analysis

Research reports

Tags

BioMarin Pharmaceutical (BMRN)

Catabasis Pharmaceuticals Inc (CATB)

Innoviva (INVA)

Ionis Pharmaceuticals Inc (IONS)

Prohost Portfolio

PTC Therapeutics (PTCT)

Regeneron Pharmaceuticals (REGN)

Sarepta Therapeutics (SRPT)

Summit Therapeutics (SMMT)

Theravance Biopharma (TBPH)

Comments (0)

Please sign in to join the discussion

Related Articles

Prohost Letters

Prohost Letter #461 ~ Preventing HIV Infection and Treating Primary Biliary Cholangitis

Prohost Letter #461 Preventing HIV Infection and Treating Primary Biliary Cholangitis Gilead Sciences Gilead Sciences’ ( GILD ) stock price has been paralyzed for more than three consecutive years. T...

Prohost Biotech

Aug 21, 2024

Prohost Letters

Prohost Letter #460 ~ Treating IgA Nephropathy

Prohost Letter #460 Treating IgA Nephropathy Immunoglobulin A ( IgA ), the antibody of the immune system known to fight infections, can itself cause two important diseases. It can attack the body caus...

Prohost Biotech

Jun 1, 2024

Prohost Letters

Prohost Letter #459 ~ NAFLD & NASH

Prohost Letter #459 ~ NAFLD & NASH NAFLD is Non-Alcoholic Fatty Liver Disease, and NASH is Non-Alcoholic Steatohepatitis. We will start with NAFLD. NAFLD The Non-Alcoholic Fatty Liver Disease is cau...

Prohost Biotech

Mar 3, 2024